Biotechnology company Moderna said that its preliminary phase three trial data show its coronavirus vaccine is now at 94.5% efficacy, just a week after Pfizer made a similar announcement about its own vaccine.
Moderna said that it evaluated 95 confirmed COVID-19 infections from the trial's 30,000 participants. Of those cases, 90 cases of the virus occurred in the placebo group, while just five occurred in the vaccinated group.
The company created the vaccine alongside the National Institute of Allergy and Infectious Diseases.
"Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters," CEO Stephane Bancel said in a statement. "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease."
Moderna said that there are no significant safety concerns about the vaccine and that it plans to start testing on teens and children soon.